

CURRICULUM VITAE
DOUGLASS WILLIAM FORSHA, M.D.

OFFICE: Jordan Valley Dermatology Center
3570 West 9000 South, Suite 220
West Jordan, Utah 84088
Phone: (801) 569-1456
Research Direct phone: (801) 316-0266
FAX: (801) 565-7931
Email: dforsha@jordanvalleydermatology.com

DEGREES EARNED

M.D.: Vanderbilt University School of Medicine, Nashville, Tennessee – 1985
B.A. (cum laude): Asian Studies – Brigham Young University, Provo, Utah – 1979

EDUCATION

Residency: Dermatology – University of Illinois College of Medicine at Chicago – 1986 – 1989
Postgraduate Internship: Internal Medicine – Vanderbilt University and Affiliated Hospitals –
1985 – 1986
Graduate: Vanderbilt University School of Medicine – 1981 – 1985
Undergraduate: Brigham Young University, Provo, Utah – 1973 – 1979

PROFESSIONAL MEMBERSHIPS

American Academy of Dermatology
American Medical Association

EXPERIENCE

Jordan Valley Dermatology, West Jordan, Utah – January 2014
Medical Director and Principal Investigator
Founded South Valley Dermatology, West Jordan, Utah – July 1991
Medical Director and Principal Investigator
Dermatology practice at Aiken Dermatology and Skin Cancer Clinic
Aiken, South Carolina – July 1989 – July 1991

CERTIFICATION AND LICENSURE

GCP Certified – Expires October 2018
Medical License – State of Utah (1056010010) – State of Wyoming (8010A)
National Board of Medical Examiners – Diplomate – 1986

HOSPITAL PRIVILEGES

Intermountain Medical Center, Murray, Utah – Courtesy Staff
Jordan Valley Medical Center, West Jordan, Utah – Active Staff
Pioneer Valley Hospital, West Valley City, Utah – Active Staff

DF
5/15/17

OTHER ACTIVITIES

Chief Organist at church in Aiken, South Carolina
Lived in Thailand 1974 – 1976 – Speak fluent Thai
Member of the Mormon Tabernacle Choir, Salt Lake City, Utah – 1973 – 1974
Enjoy snow skiing, swimming and racquetball

PREVIOUS AND ONGOING RESEARCH EXPERIENCE DOUGLASS WILLIAM FORSHA, M.D.

Evaluation of efficacy, duration of remission and safety of a light and occlusive patch therapy for plaque psoriasis.

Dec 2016/Current

SPONSOR: Luma Therapeutics, Inc.

A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of XXX Cream, 1% and XXX Cream, 1% in Patients with Mild to Moderate Atopic Dermatitis.

Dec 2016/Current

SPONSOR: DPT Laboratories, Ltd., a Division of Mylan

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of XXX for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study XXX

Jun 2016/Current

SPONSOR: Foamix Pharmaceuticals

A randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8 –week Regimens XXX, 10% Topical Solution (Taro Pharmaceuticals, USA, Inc.) in Patients with Mild to Moderate Onychomycosis

Mar 2016/Current

SPONSOR: Taro Pharmaceuticals, USA

XXX versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment

Mar 2016/May 2016

SPONSOR: Boehringer Ingelheim

An Open-label Study to Evaluate the Safety and Tolerability of XXX topical solution, 5% in the Treatment of Onychomycosis of the Toenail in Pediatric Patients Aged 6 to 16 Years and 11 Months.

March 2016/Current

SPONSOR: Anacor

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXX in Treatment-Resistant Pruritus Associated with Atopic Dermatitis

Mar 2016/Current

SPONSOR: Vanda Pharmaceuticals, Inc.